CLOs on the Move


 
Creo is an ingredient company that produces rare and novel cannabinoids using the age-old natural process of fermentation, coupled with cutting-edge technological innovation. Founded in 2016 and based in California, Creo`s mission is to enable the creation of cannabinoid products that help people everywhere while doing less harm to the planet. Creo`s technology partner and major shareholder is industry-leading biotech firm Genomatica.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Cassava Sciences

Cassava Sciences, Inc. is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer`s disease. Our novel science is based on stabilizing – but not removing – a critical protein in the brain.

Biolin Scientific

Biolin Scientific is a Linthicum Heights, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Noramco

Noramco, Inc. is a Wilmington, DE-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Kyn Therapeutics

Kyn Therapeutics is building a new generation of immuno-oncology therapies targeting powerful immunosuppressive metabolic networks. We envision a future where immunotherapies are the foundation of every cancer patient`s treatment, delivering rapid and durable responses. The Kyn team is composed of drug hunters, translational researchers and entrepreneurs drawn from many of the largest innovators in biotechnology supported by world-class advisors, and is backed by a seasoned board of directors anchored by OrbiMed Healthcare Fund Management and Atlas Venture. Kyn Therapeutics is headquartered in the biotech hub of Cambridge, Massachusetts.

Thrive Bioscience

Thrive Bioscience`s unique solutions increase the speed, quality, and cost-effectiveness of drug discovery and basic research while enabling the delivery of new therapies through improving the cell culture and stem cell culture processes.